Mr Mahmood is a consultant ophthalmologist specialising in medical retina. He graduated from Cambridge University in 1997 and initially built up his general medical skills by working in Accident and Emergency. He joined the world-renowned Manchester Royal Eye Hospital in 2000 and did his general ophthalmology training. In 2006 he developed his interest in retinal disease as a senior clinical and research fellow at Royal Liverpool University Hospital. In 2008 he was appointed as a consultant ophthalmologist in Manchester Royal Eye with subspecialist expertise in medical retina.
Mr Mahmood is an expert in his field and has presented at national and international meetings. He has also worked as an advisor to the pharmaceutical industry in the development of new treatments for macular diseases including age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. He is active in teaching and research and as well as organising teaching for ophthalmic trainees he has run courses for optometrists, general practitioners and specialist colleagues. Mr Mahmood has published and conducted research into age-related macular degeneration treatments and diabetic retinopathy.
Mr Mahmood is a member of the Royal College of Ophthalmologists and the American Academy of Ophthalmology. He holds an honorary clinical lectureship with the University of Manchester. He is on the Royal College panel of assessors for certifying the eligibility for specialist registration.
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 . The Manchester Royal Eye Hospital (MREH),...